August 20, 2025

James Bianco
Chief Executive Officer
TuHURA Biosciences, Inc.
10500 University Center Drive, Suite 110
Tampa, FL 33612

       Re: TuHURA Biosciences, Inc.
           Registration Statement on Form S-1
           Filed August 12, 2025
           File No. 333-289532
Dear James Bianco:

       We have conducted a limited review of your registration statement and
have the
following comment.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe our comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-1
General

1.     We note that you are registering certain securities for resale that you
have agreed to
       issue in connection with a private placement for an aggregate offering
price of $12.6
       million. We also note that of the $12.6 million offering, $8.9 million
was purchased in
       four equal tranches with the remaining $3.7 million required to be
purchased and
       funded by December 31, 2025. Please provide us with your analysis as to
how you are
       eligible to register the resale of the $3.7 million worth of securities
that have not yet
       been issued in this private placement or otherwise advise. Refer to
Securities Act
       Sections Compliance and Disclosure Interpretations Question 139.11 for
guidance.
       We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
 August 20, 2025
Page 2

of action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Tyler Howes at 202-551-3370 or Tim Buchmiller at
202-551-3635
with any questions.



                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Curt P. Creely, Esq.